Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

about

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

Item

http://www.wikidata.org/entity/Q49582579

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

@en

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

@nl

type

Item

label

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

@en

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

@nl

prefLabel

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

@en

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

@nl

P1476

Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.

@en

P2093

Hye Sun Gwak

http://www.w3.org/2001/XMLSchema#string

Jae Youn Kim

http://www.w3.org/2001/XMLSchema#string

Jeong Yee

http://www.w3.org/2001/XMLSchema#string

Sandy Jeong Rhie

http://www.w3.org/2001/XMLSchema#string

Soyeon Cho

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.

ABC multidrug transporters: structure, function and role in chemoresistance.

Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Rechallenge with gefitinib following severe drug-induced hepatotoxicity in a patient with advanced non-small cell lung cancer: A case report and literature review.

P304

263-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.1010

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28981161

http://www.w3.org/2001/XMLSchema#string

P921

hepatotoxicity